서방약 시장 보고서(2026년)

Extended-release drugs are dosage forms designed to deliver medication over an extended period at a predetermined rate, duration, and site in a controlled manner. Compared to immediate-release formulations, these drugs are taken less frequently, allowing patients to take one or two doses per day instead of three or four.

The main types of extended-release drugs include sustained-release drugs and controlled-release drugs. Sustained-release drugs are medications formulated to release their active ingredients gradually in the body over time, primarily to maintain consistent therapeutic levels. These drugs are available as both over-the-counter and prescription products and are distributed through hospital pharmacies, retail pharmacies, mail-order pharmacies, and drug store channels.

Tariffs have affected the extended-release drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and advanced drug delivery materials, impacting production expenses and timelines. Prescription and sustained-release drug segments are particularly sensitive, while regions like North America and Europe, which rely on API imports from Asia-Pacific, are most affected. Despite challenges, tariffs have encouraged local sourcing and domestic manufacturing investments, potentially fostering innovation in cost-efficient extended-release drug solutions.

The extended-release drugs market research report is one of a series of new reports from The Business Research Company that provides extended-release drugs market statistics, including extended-release drugs industry global market size, regional shares, competitors with a extended-release drugs market share, detailed extended-release drugs market segments, market trends and opportunities, and any further data you may need to thrive in the extended-release drugs industry. This extended-release drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The extended-release drugs market size has grown rapidly in recent years. It will grow from $69.63 billion in 2025 to $77.92 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, demand for patient-centric drug formulations, limitations of immediate-release drugs, increasing healthcare expenditure, advancements in pharmaceutical excipients.

The extended-release drugs market size is expected to see rapid growth in the next few years. It will grow to $126.89 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to growth of precision medicine, increasing adoption of oral controlled-release formulations, expansion of hospital and retail pharmacies, rising geriatric population, investment in novel delivery technologies. Major trends in the forecast period include personalized dosage regimens, advanced drug delivery systems, patient adherence optimization, novel formulation technologies, extended-release combination therapies.

The growing incidence of chronic conditions is anticipated to drive the expansion of the extended-release drug market in the coming years. Chronic conditions are illnesses that persist for one year or longer and require ongoing medical management, limit daily activities, or both. Common examples include heart disease, cancer, obesity, and diabetes. Extended-release drug delivery systems are formulated to release medication at a controlled rate over an extended period, maintaining stable drug concentrations in the body. This approach helps sustain consistent therapeutic effects and minimizes the fluctuations in drug levels often associated with immediate-release formulations. For example, in January 2023, according to the National Center for Biotechnology Information, a US-based National Library of Medicine, it was projected that by 2050, the number of individuals aged 50 years and older living with at least one chronic condition would increase by 99.5%, reaching approximately 142.66 million. Consequently, the rising burden of chronic conditions is contributing to the growth of the extended-release drug market.

Major companies operating in the extended-release drugs market are focusing on the development of innovative products, such as next-generation extended-release tablets, to strengthen their product portfolios and gain a competitive advantage. Extended-release tablets are pharmaceutical formulations engineered to gradually release active ingredients over a prolonged duration. For instance, in February 2023, Teva Pharmaceutical Industries Ltd. received approval from the U.S. Food and Drug Administration for Austedo XR (deutetrabenazine). Austedo XR is indicated for the treatment of adults with chorea associated with Huntington disease and tardive dyskinesia and is available in 6 mg, 12 mg, and 24 mg dosage strengths. The approval of Austedo XR provides patients with an additional effective treatment option that allows for once-daily administration, offering a more convenient and efficient therapeutic alternative for managing these movement disorders.

In April 2024, ProMed Pharma, a US-based provider of polymer-based drug delivery dosage forms and combination device components, acquired the manufacturing operational assets of SpineThera for an undisclosed amount. Through this acquisition, ProMed Pharma aims to expand its technological capabilities in sustained- and extended-release drug formulations by incorporating SpineThera's biodegradable microsphere manufacturing platform. SpineThera specializes in the development of novel extended-release injectable therapies using proprietary micro-suspension technology.

Major companies operating in the extended-release drugs market are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Watson Pharmaceuticals Inc.

North America was the largest region in the extended-release drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the extended-release drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The extended-release drug market consists of sales of extended-release tablets, extended-release capsules, and implants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Extended-Release Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses extended-release drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for extended-release drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The extended-release drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Sustained Release Drug; Controlled Release Drug
• 2) By Mode: Over-The-Counter; Prescription
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Mail Order Pharmacies; Drug Stores
• Subsegments:
• 1) By Sustained Release Drug: Matrix Systems; Coating Systems
• 2) By Controlled Release Drug: Osmotic Systems; Microencapsulation Systems; Targeted Delivery Systems
• Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Novartis AG; Sanofi SA; GlaxoSmithKline PLC; AstraZeneca Plc; Gilead Sciences Inc.; Boehringer Ingelheim International GmbH; Viatris Inc.; Teva Pharmaceuticals Inc.; Sun Pharmaceutical Industries Limited; Purdue Pharma LP; Amneal Pharmaceuticals Inc.; Endo Pharmaceuticals Inc.; Mallinckrodt LLC; Allergan plc; Janssen Pharmaceuticals Inc.; Noven Pharmaceuticals Inc.; Mayne Pharma Group Ltd.; Neos Therapeutics Inc.; Oakwood Laboratories LLC; Roxane Laboratories Inc.; Watson Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Extended-Release Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Extended-Release Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Extended-Release Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Extended-Release Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Artificial Intelligence & Autonomous Intelligence
• 4.2. Major Trends
  • 4.2.1 Personalized Dosage Regimens
  • 4.2.2 Advanced Drug Delivery Systems
  • 4.2.3 Patient Adherence Optimization
  • 4.2.4 Novel Formulation Technologies
  • 4.2.5 Extended-Release Combination Therapies

5. Extended-Release Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Retail Pharmacies
• 5.3 Clinics
• 5.4 Mail-Order Pharmacies
• 5.5 Patients

6. Extended-Release Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Extended-Release Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Extended-Release Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Extended-Release Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Extended-Release Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Extended-Release Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Extended-Release Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Extended-Release Drugs Market Segmentation

• 9.1. Global Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sustained Release Drug, Controlled Release Drug
• 9.2. Global Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Over-The-Counter, Prescription
• 9.3. Global Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores
• 9.4. Global Extended-Release Drugs Market, Sub-Segmentation Of Sustained Release Drug, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Matrix Systems, Coating Systems
• 9.5. Global Extended-Release Drugs Market, Sub-Segmentation Of Controlled Release Drug, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems

10. Extended-Release Drugs Market Regional And Country Analysis

• 10.1. Global Extended-Release Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Extended-Release Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Extended-Release Drugs Market

• 11.1. Asia-Pacific Extended-Release Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Extended-Release Drugs Market

• 12.1. China Extended-Release Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Extended-Release Drugs Market

• 13.1. India Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Extended-Release Drugs Market

• 14.1. Japan Extended-Release Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Extended-Release Drugs Market

• 15.1. Australia Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Extended-Release Drugs Market

• 16.1. Indonesia Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Extended-Release Drugs Market

• 17.1. South Korea Extended-Release Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Extended-Release Drugs Market

• 18.1. Taiwan Extended-Release Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Extended-Release Drugs Market

• 19.1. South East Asia Extended-Release Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Extended-Release Drugs Market

• 20.1. Western Europe Extended-Release Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Extended-Release Drugs Market

• 21.1. UK Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Extended-Release Drugs Market

• 22.1. Germany Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Extended-Release Drugs Market

• 23.1. France Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Extended-Release Drugs Market

• 24.1. Italy Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Extended-Release Drugs Market

• 25.1. Spain Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Extended-Release Drugs Market

• 26.1. Eastern Europe Extended-Release Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Extended-Release Drugs Market

• 27.1. Russia Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Extended-Release Drugs Market

• 28.1. North America Extended-Release Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Extended-Release Drugs Market

• 29.1. USA Extended-Release Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Extended-Release Drugs Market

• 30.1. Canada Extended-Release Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Extended-Release Drugs Market

• 31.1. South America Extended-Release Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Extended-Release Drugs Market

• 32.1. Brazil Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Extended-Release Drugs Market

• 33.1. Middle East Extended-Release Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Extended-Release Drugs Market

• 34.1. Africa Extended-Release Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Extended-Release Drugs Market, Segmentation By Type, Segmentation By Mode, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Extended-Release Drugs Market Regulatory and Investment Landscape

36. Extended-Release Drugs Market Competitive Landscape And Company Profiles

• 36.1. Extended-Release Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Extended-Release Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Extended-Release Drugs Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis

37. Extended-Release Drugs Market Other Major And Innovative Companies

• AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc.

38. Global Extended-Release Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Extended-Release Drugs Market

40. Extended-Release Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Extended-Release Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Extended-Release Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Extended-Release Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer